CNPV
March 19, 2026
FDA approves Wegovy (semaglutide) 7.2mg under the Commissioner’s National Priority Voucher program
FDA has approved Wegovy (semaglutide) high dose 7.2mg under the Commissioner’s National Priority Voucher program. The FDA press release stated the approval decision was granted 54 days after the filing was accepted.
